These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 7577199)

  • 21. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients.
    Bruzzone M; Miglietta L; Franzone P; Gadducci A; Boccardo F
    Gynecol Oncol; 2004 May; 93(2):345-52. PubMed ID: 15099944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.
    Sehouli J; Koensgen D; Oskay-Ozcelik G; Mustea A
    Crit Rev Oncol Hematol; 2008 Sep; 67(3):204-12. PubMed ID: 18407513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
    Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
    Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
    J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
    Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
    Gadducci A; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study.
    Bruner DW; Barsevick A; Tian C; Randall M; Mannel R; Cohn DE; Sorosky J; Spirtos NM
    Qual Life Res; 2007 Feb; 16(1):89-100. PubMed ID: 17033909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors to consider when designing phase III clinical trials involving economic evaluations.
    van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
    Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic analysis during phase III clinical trials: who, what, when, where, and why?
    Bennett CL; Westerman IL
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):169-75. PubMed ID: 8608049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04.
    Owen JB; Grigsby PW; Caldwell TM; Konski AA; Johnson DJ; Demas WF; Movsas B; Jones CU; Wasserman TH
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):633-9. PubMed ID: 11172943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial.
    Markman M
    Curr Oncol Rep; 2012 Dec; 14(6):480-2. PubMed ID: 22923018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.